Methods of enhancing bioactivity of chemokines

Details Methods of enhancing bioactivity of chemokines Methods of enhancing bioactivity of chemokines

1999-12-20

2002-06-04

Stucker, Jeffrey (Department: 1647)

Drug, bio-affecting and body treating compositions

Lymphokine

C514S002600, C514S012200

Reexamination Certificate

active

06399053

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates generally to certain proteins and to methods of improving the biological activity of certain proteins, and more specifically, chemokines.
BACKGROUND OF THE INVENTION
All the members of the intercrine or chemokine family are basic heparin-binding polypeptides which have four cysteine residues which form two disulfide bridges. All these proteins which have been functionally characterized appear to be involved in proinflammatory and/or restorative functions. As such, these molecules are anticipated to have therapeutic potential in bone marrow transplantation and the treatment of infections, cancer, myelopoietic dysfunction, graft versus host disease, and autoimmune diseases.
The chemokine family can be divided into two subfamilies depending upon their amino acid sequence and chromosomal location. The members of the &agr; subfamily are termed the “C-X-C” subfamily because the first two cysteines are separated by only one amino acid. The human genes in this subfamily include IL-8, GRO/MGSA, and IP-10; murine counterparts include KC and macrophage inflammatory protein 2 (MIP-2). In the chemokine &bgr; subfamily, the first two cysteines are in an adjacent position (the “C-C” subfamily). This subfamily includes human MCAF, LD-78, ACT-2, and RANTES. The murine counterparts are JE, TCA-3, MIP-1&agr;, and MIP-1&bgr; [J. J. Oppenheim et al,
Annu. Rev. Immunol
., 9:617-648 (1991)].
The murine KC gene product [Oquendo et al,
J. Biol. Chem
., 264:4233 (1989)] is induced by platelet-derived growth factor (PDGF) and this is thought to be the murine homolog of the human MGSA/gro&agr; gene (63.0% amino acid identity to mMIP-2). KC has been expressed in COS-1 cells to show that it encodes a secreted protein [Oquendo, cited above].
Two forms of MIP have been found in cultures of macrophage tumor cells from the mouse: MIP-1 and MIP-2. Murine MIP-2 (mMIP-2) is an inducible protein whose cDNA also has been cloned and sequenced [International Patent Application, Publication No. WO 90/02762 (Mar. 22, 1990)]. Murine MIP-2 has been shown to have potent chemotactic activity for human polymorphonuclear leukocytes (PMN), and to induce PMN degranulation of lysozyme but not of &bgr;-glucuronidase [Wolpe et al,
J. Exp. Med
., 167:570 (1987)]. Further, mMIP-2 has been shown to have myelopoietic enhancing activities for CFU-GM [Broxmeyer et al,
J. Exp. Med
., 170:1583 (1989)]. The human counterpart of this factor was found to consist of two species, MIP-2&agr; and MIP-2&bgr;, also termed gro-&bgr; and gro-&ggr;, respectively.
The cDNA and amino acid sequences of human gro-&bgr; are provided in International Patent Application, Publication No. WO 92/00327 (Jan. 9, 1992); the cDNA and amino acid sequences of human gro-&ggr; are provided in International Patent Application, Publication No. WO 92/00326 (Jan. 9, 1992). Each of these sequences were predicted to encode a 73 amino acid mature protein.
MGSA or gro-&agr; [Richmond et al,
EMBO J
., 7:2025 (1988)] is an autocrine growth factor with potent mitogenic activity secreted by human melanoma cells and is the product of the human gro gene [Anisowicz et al,
Proc. Natl. Acad. Sci
., 84:7188 (1987)].
There remains a need in the art for methods of enhancing the bioactivity of these mature proteins to enable their efficient use as therapeutic or pharmaceutical products, and to minimize the amounts of the proteins necessary to produce a therapeutic effect, thereby lowering toxicity.
SUMMARY OF THE INVENTION
In one aspect, the present invention provides a modified chemokine, which includes KC protein, human gro &agr;, gro-&bgr;, and gro-&ggr;, which modified protein is characterized by truncation of between about 2 to about 8 amino acids at the amino terminus of the mature protein and by at least a log higher biological activity than the mature protein.
In another aspect, the present invention provides a modified chemokine which is characterized by truncation of between about 2 to about 10 amino acids at the carboxy terminus of the mature protein and by at least a log higher biological activity than the mature protein.
In still another aspect, the present invention provides a multimeric protein which comprises an association of two or more modified proteins of this invention. These multimers preferably contain multiple copies of the same modified protein, e.g., a dimer of truncated KC protein. However, multimeric forms of two or more different modified proteins of this invention are also included in this invention. Multimeric forms of a modified protein of this invention and another known mature protein are also encompassed by this invention.
In a further aspect, the present invention provides a method of enhancing the biological activity of chemokines by modifying and/or truncating the proteins as described above.
In yet another aspect, the present invention provides pharmaceutical and diagnostic compositions containing the modified and multimeric proteins of the invention, as well as methods for administering same in therapeutic treatments.
In a further aspect, the present invention provides antibodies characterized by the ability to selectively bind the modified chemokines of the invention.
In still another aspect, the present invention provides a method of monitoring the effect of a selected hematopoiesis stimulating agent upon hematopoietic synergistic factor (HSF) in vivo through use of an antibody of the invention.
In yet another aspect, the present invention provides a method of inducing HSF in vivo by administering (pGlu-Glu-Asp)
2
-Sub-(Lys)
2
[SEQ ID NO: 5].
Other aspects and advantages of the present invention are described further in the following detailed description of the preferred embodiments thereof.


REFERENCES:
patent: 5154921 (1992-10-01), Sager et al.
patent: 5459128 (1995-10-01), Rollins et al.
patent: 5703206 (1997-12-01), Wolpe
patent: 5739103 (1998-04-01), Rollins et al.
patent: 5854412 (1998-12-01), Rollins et al.
patent: 6080398 (2000-06-01), Pelus et al.
patent: WO 91/07988 (1991-06-01), None
patent: WO 92/00327 (1992-01-01), None
patent: WO 92/01039 (1992-01-01), None
patent: WO 92/06196 (1992-04-01), None
patent: WO 94/28916 (1994-12-01), None
patent: WO 96/19234 (1996-06-01), None
E. Brandt, et al., “Novel Molecular Variant of the Neutrophil-Activating Peptide NAP-2 With Enhanced Biological Activity is Truncated at the C-Terminus: Identification By Antibodies With Defined Epitope Specificity”, (1993), Molecular Immunology, vol. 30:11, pp. 979-991.
B. Moser, et al., “Interleukin-8 Antagonists Generated by N-terminal Modification”, (1993), Journal of Biological Chemistry, vol. 268:10, pp. 7125-7128.
C.A. Hérbert, et al., “Endothelial and Leukocyte Forms of IL-8”, (1990), Journal of Immunology, vol. 145:9, pp. 3033-3040.
J. Van Damme, “The neutrophil-activating proteins interleukin 8 and &bgr;-thromboglobulin: in vitro and in vivo comparison of NH2-terminally processed forms”, (1990), European Journal of Immunology, vol. 20, pp. 2113-2118.
A.M. Gronenborn, et al., “Modeling, the three-dimensional structure of the monocyte chemo-attractant and activating protein MCAF/MCP-1 on the basis of the solution structure of interleukin-8”, (1991), Protein Engineering, vol. 4:3, pp. 263-269.
J.J. Oppenheim, et al., “Properties of the Novel Proinflammatory Supergene “Intercrine” Cytokine Family”, Annual Review of Immunology, vol. 9, pp. 617-648.
S. Nourshargh, et al., “A Comparative Study of the Neutrophil Stimulatory Activity In Vitro and Pro-Inflammatory Properties In Vivo of 72 Amino Acid and 77 Amino Acid IL-8”, (1992), Journal of Immunology, vol. 148:1, pp. 106-111.
I. Clark-Lewis, et al., “Structure-Activity Relationships of Interleukin-8 Determined Using Chemically Synthesized Analogs”, (1991), Journal of Biological Chemistry, vol. 266:34, pp. 23128-23134.
Proost, et al., “Identification of Novel Granulocyte Chemotactic Protein (GCP-2) from Human Tumor Cells”, (1993), Journal of Immunology, vol. 150:3

Affiliated with

Also associated with

Rating

Methods of enhancing bioactivity of chemokines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of enhancing bioactivity of chemokines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of enhancing bioactivity of chemokines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2907527